Join Dr. Anna Honko and Dr. Doug Reed as they discuss methods and applications for infectious disease research including coronavirus-based illnesses.

Increasing world populations and ease of international travel are driving the necessity for better preparedness to protect the public from infectious disease outbreaks, as is evident with the coronavirus outbreak of 2019 and 2020. The scientific community works tirelessly to identify prevention and treatment options but are chasing a villain that changes form as the virus mutates. Research to identify virus-specific and universal vaccines as well as effective treatments is on-going.

In this webinar, Dr. Anna Honko, Research Associate Professor, Microbiology at Boston University School of Medicine, provides a past-perspective overview of infectious disease research using telemetry as well as a preview of upcoming SARS-CoV-2 based approaches. Dr. Honko explores the need to maximize endpoints collected in non-human primates to draw better conclusions while supporting the Animal Rule and trigger-to-treat studies.

Dr. Doug Reed, Associate Professor of Immunology at the University of Pittsburgh Center for Vaccine Research, provides examples using a translational multi-species approach to study COVID-19. In addition, Dr. Reed highlights data analysis methods for post-exposure telemetry and plethysmography.

Key Topics Include:

  • Range of species used in infectious disease and coronavirus research
  • Model development techniques using a variety of scientific instrumentation
  • Physiologic endpoints used for both biomarkers and post infection monitoring

Presenters

Associate Professor
School of Medicine
Boston University

Anna Honko, PhD recently joined Boston University’s National Emerging Infectious Diseases Laboratories (NEIDL) as a Research Associate Professor. In the Nonclinical Studies Unit, she’ll be directing well-documented, Animal Rule and GLP studies to advance anti-viral medical countermeasure development. Dr. Honko's background is in immunology and vaccine development, with a later emphasis in biothreat and emerging infectious diseases. She has a focus on regulated studies as well a passion for radiotelemetry monitoring.

Associate Professor of Immunology
Center for Vaccine Research, School of Medicine
University of Pittsburgh

Production Partner

Data Sciences International

Data Sciences International (DSI) is the leader in preclinical physiological monitoring offering telemetry, instrumentation, software and services to help advance science. Industries served include: Pharmaceuticals, Academia, Contract Research Organizations, Biological and Chemical Defense, Medical Devices, Government, and Biotechnology.

Harvard Bioscience, Inc.

Harvard Bioscience is a global leader in the manufacturing and distribution of solutions to advance life science research. For over 110 years, we have served the changing needs of life scientists in over 100 countries. Our expanding portfolio of brands include instruments for organ and animal research, cell analysis, molecular biology, fluidics, and laboratory consumables.

Additional Content From Data Sciences International

Additional Content From Harvard Bioscience, Inc.

Related Content

Preclinical Animal Models of IBD, GVHD, and Pulmonary Disease

Preclinical Animal Models of IBD, GVHD, and Pulmonary Disease

Join BioModels’ Scientists, Andrew Borkowski, PhD and Nicole Smith, PhD, as they discuss a selection of key preclinical models of inflammatory disease, including models of Inflammatory Bowel Disease (IBD)/colitis, Graft vs Host Disease (GvHD), and pulmonary disease, focusing on the utility of clinically relevant endpoints that create highly translational models of human disease.